The effect of the probiotic supplement—ASTARTE™—on the reduction of recurrent urinary tract infection in women aged 18-40 years: protocol for a randomized, double-blind, placebo-controlled study | Synapse
April 10, 2026Open Access
The effect of the probiotic supplement—ASTARTE™—on the reduction of recurrent urinary tract infection in women aged 18-40 years: protocol for a randomized, double-blind, placebo-controlled study
Key Points
To investigate the effectiveness of the probiotic supplement Astarte in reducing recurrent urinary tract infections in women aged 18-40.
Conducted a randomized, double-blind, placebo-controlled trial.
Involves women aged 18-40 with recurrent urinary tract infections.
Participants received either Astarte probiotic or a placebo.
The study aims to identify significant differences in infection rates between the probiotic and placebo groups.
Expected outcomes include reduced recurrence of infections in the probiotic group.
Abstract
ClinicalTrials.gov Identifier: NCT05553652. Registered 21 September 2022.